Compare Merck & Co., Inc. (MRK) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while iShares 10 20 Year Treasury Bond ETF trades at $92.19 (market cap $11.02B). The key difference: Merck & Co., Inc. is far larger — about 31.9× iShares 10 20 Year Treasury Bond ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares 10 20 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| MRK | TLH | |
|---|---|---|
Market Cap | $351.28B | $11.02B |
Volume | 7,969,665 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $105.36 |
52-Week Low | $82.49 | $91.34 |
Typical Hold Time | 98 Days | 60 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
TLH (iShares 10-20 Year Treasury Bond ETF) trades at $92.11, up 0.72% with bearish technical signals from moving averages. The ETF shows unusually high trading volume, up 66% recently, amid a challenging bond market environment where 10-year Treasury yields have reached multi-decade highs. Recent dividend payments of $0.36-$0.38 reflect the fund's income-generating nature.
Outlook remains cautious as rising bond yields pressure long-term Treasury ETFs. Investment opportunity exists for income-focused investors seeking regular dividends, but risks include continued yield increases and Federal Reserve policy uncertainty. The bearish technical picture suggests near-term pressure on bond ETF valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
